Sintra, 30th June 2021 – Labatec inaugurated its first factory in Portugal, in the presence of the Secretary of State for Internationalization, Eurico Brilhante Dias, the Infarmed Vice President, António Faria Vaz, the Swiss Ambassador to Portugal, André Regil and the Mayor of Sintra, Basílio Horta.
The project started in January 2018, and three years later, after an investment of 15 million euros and the hiring of 40 Portuguese employees, Labatec now officially starts the production of medicines in Portugal, more precisely in Sintra. All the production of medicine is destined for export markets in Switzerland, Middle East and North Africa region. current capacity. Labatec also offers its capacity for other European partners to manufacture their products at a state-of-the-art manufacturing site and export to their global markets.
With an area of around 4,000m2, which includes offices, production, packaging, laboratories and a warehouse, the new manufacturing site is equipped with the latest technology and designed following the latest and highest European standards of Good Manufacturing Practice (GMP). Designed with the future in mind, this new factory has an initial production capacity of 250 million tablets, making it possible, and quickly, to expand to 2 billion tablets per year, at its maximum.
Labatec is a Swiss-based private pharmaceutical company with over 60 years of experience in the production and supply of high-quality medicines to Switzerland, the Middle East and North Africa. With an extensive portfolio, comprising more than 70 products and 280 references. Labatec develops medicines (solid oral tablets) focused on the musculoskeletal system and exports to various markets, medicines for ophthalmology, analgesics, women’s health, among others. Labatec was acquired in 2008 by Dr. Samih Darwazah, founder of Hikma Pharmaceuticals PLC, a pharmaceutical listed on the London Stock Exchange and operating in more than 31 countries.
Contact us for more information
Labatec Pharma SA, 1217 Meyrin (GE)